Menu
Search
|

Menu

Close
X

Trillium Therapeutics Inc TRIL.OQ (NASDAQ Stock Exchange Capital Market)

7.15 USD
-0.20 (-2.72%)
As of Feb 16
chart
Previous Close 7.35
Open 7.60
Volume 9,294
3m Avg Volume 27,506
Today’s High 7.65
Today’s Low 7.10
52 Week High 13.30
52 Week Low 4.10
Shares Outstanding (mil) 10.79
Market Capitalization (mil) 70.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, CAD)
FY17
0
FY16
0
FY15
0
EPS (CAD)
FY17
-3.915
FY16
-4.057
FY15
-2.383
*Note: Units in Millions of Canadian Dollars
**Note: Units in Canadian Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
3.10
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.19
16.52
LT Debt to Equity (MRQ)
vs sector
0.19
12.22
Return on Investment (TTM)
vs sector
-52.37
14.43
Return on Equity (TTM)
vs sector
-126.37
16.13

EXECUTIVE LEADERSHIP

Calvin Stiller
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Niclas Stiernholm
President, Chief Executive Officer, Director, Since 2013
Salary: $450,000.00
Bonus: --
James Parsons
Chief Financial Officer, Since 2011
Salary: $275,000.00
Bonus: --
Malik Slassi
Senior Vice President - Discovery Research, Since
Salary: --
Bonus: --
Robert Uger
Chief Scientific Officer, Since 2013
Salary: $320,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2488 Dunwin Dr
MISSISSAUGA   ON   L5L 1J9

Phone: +1416.5950627

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.

SPONSORED STORIES